| Paul H Eun, MD | |
|
1701 3rd St Se, Suite 200, Puyallup, WA 98372-4511 | |
| (253) 840-4444 | |
| (253) 840-5239 |
| Full Name | Paul H Eun |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 41 Years |
| Location | 1701 3rd St Se, Puyallup, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841393865 | NPI | - | NPPES |
| 7085020 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD00031953 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tacoma General Allenmore Hospital | Tacoma, WA | Hospital |
| Entity Name | Dedicated Womens Health Specialists Inc P.s. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750597480 PECOS PAC ID: 4082500392 Enrollment ID: O20040224000965 |
News Archive
School dinners have come under the spotlight recently, but new research suggests that diet in the pre-school years is even more important.
Cancer has a mighty big bag of tricks that it uses to evade the body's natural defense mechanisms and proliferate. Among those tricks is one that allows tumor cells to turn the intricate and extensive system of lymphatic vessels into something of a highway to metastasis. Yet research unveiled this week may aid in the development of therapeutics that will put the brakes on such cancer spread, and the researchers who completed the study say the findings may extend to other lymphatic disorders.
Dune Medical Devices today announced the completion of patient enrollment in the MarginProbe™ pivotal clinical trial. The MarginProbe procedure provides surgeons with real-time detection of cancer at the edges of the tissue removed during breast conservation surgery (BCS), which is the only way to ensure the complete removal of the tumor from the breast. The randomized, controlled trial includes 664 women who underwent BCS at one of 21 leading medical facilities, with 18 in the US and three in Israel.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN, for the treatment of gastric cancers.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul H Eun, MD 1701 3rd St Se, Suite 200, Puyallup, WA 98372-4511 Ph: (253) 840-4444 | Paul H Eun, MD 1701 3rd St Se, Suite 200, Puyallup, WA 98372-4511 Ph: (253) 840-4444 |
News Archive
School dinners have come under the spotlight recently, but new research suggests that diet in the pre-school years is even more important.
Cancer has a mighty big bag of tricks that it uses to evade the body's natural defense mechanisms and proliferate. Among those tricks is one that allows tumor cells to turn the intricate and extensive system of lymphatic vessels into something of a highway to metastasis. Yet research unveiled this week may aid in the development of therapeutics that will put the brakes on such cancer spread, and the researchers who completed the study say the findings may extend to other lymphatic disorders.
Dune Medical Devices today announced the completion of patient enrollment in the MarginProbe™ pivotal clinical trial. The MarginProbe procedure provides surgeons with real-time detection of cancer at the edges of the tissue removed during breast conservation surgery (BCS), which is the only way to ensure the complete removal of the tumor from the breast. The randomized, controlled trial includes 664 women who underwent BCS at one of 21 leading medical facilities, with 18 in the US and three in Israel.
Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted an Orphan Drug Designation (ODD) for its lead product candidate, REOLYSIN, for the treatment of gastric cancers.
› Verified 3 days ago
Alexinna Ciana Johns, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1322 3rd St Se Ste 240, Puyallup, WA 98372 Phone: 253-697-5757 | |
Mrs. Michelle Dawn Fears, WHNP Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 400 15th Ave Se, Puyallup, WA 98372 Phone: 253-697-1310 | |
Dr. Virginia O White, Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1450 5th St Se Ste 3200, Puyallup, WA 98372 Phone: 253-697-3550 | |
Laurie J Morris, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1701 3rd St Se, Suite 200, Puyallup, WA 98372 Phone: 253-840-4444 Fax: 253-840-5239 | |
Victor L Obregon, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1703 S Meridian Ste 103, Puyallup, WA 98371 Phone: 253-848-2453 | |
Jonathan Christopher Mitchell, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 11102 Sunrise Blvd E, Suite 110, Puyallup, WA 98374 Phone: 253-697-7350 Fax: 253-841-5962 | |
Sam Hwa Song, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1408 3rd St Se, 150 & 200, Puyallup, WA 98372 Phone: 253-697-3550 |